Barcelona Liver Bioservices announces collaboration with Conatus Pharmaceuticals

10 November, 2017

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Conatus Pharmaceuticals, biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

Under the terms of the agreement, which combines the scientific and technical expertise of both companies, BLB will perform cutting-edge research to understand the mechanisms underlying the beneficial effects of Conatus’ lead compound emricasan on liver cirrhosis and portal hypertension.

For more information about the services and research developed by BLB please visit www.liver.barcelona